May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Ophthalmic Complications Following Treatment of Primary Orbital and/or Paranasal Sinus Rhabdomyosarcoma
Author Affiliations & Notes
  • P.D. Gandhi
    Ophthalmology, Univ of Tennessee Health Science Center, Memphis, TN
    Surgery, St. Jude Children's Research Hospital, Memphis, TN
  • J.C. Fleming
    Ophthalmology, Univ of Tennessee Health Science Center, Memphis, TN
    Surgery, St. Jude Children's Research Hospital, Memphis, TN
  • B.G. Haik
    Ophthalmology, Univ of Tennessee Health Science Center, Memphis, TN
    Surgery, St. Jude Children's Research Hospital, Memphis, TN
  • M.W. Wilson
    Ophthalmology, Univ of Tennessee Health Science Center, Memphis, TN
    Surgery, St. Jude Children's Research Hospital, Memphis, TN
  • Footnotes
    Commercial Relationships  P.D. Gandhi, None; J.C. Fleming, None; B.G. Haik, None; M.W. Wilson, None.
  • Footnotes
    Support  Research to Prevent Blindness, Inc., New York, NY
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5400. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P.D. Gandhi, J.C. Fleming, B.G. Haik, M.W. Wilson; Ophthalmic Complications Following Treatment of Primary Orbital and/or Paranasal Sinus Rhabdomyosarcoma . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5400.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To identify the type and frequency of ocular and orbital complications observed following treatment for primary rhabdomyosarcoma of the orbit and/or paranasal sinuses. Methods: A retrospective chart review was performed to identify all patients treated at one institution from 1972 to the present with biopsy–proven rhabdomyosarcoma of the orbit and/or paranasal sinuses. All patients were treated with a combination of chemotherapy and/or radiation. Pre–treatment and follow–up data were extracted from the patients’ medical records. Results: A total of 21 patients (12 male, 9 female) of median age 7.0 years (range 1.0 – 14.5 years) with primary orbital (19) or sinus (2) rhabdomyosarcoma (17 embryonal, 3 alveolar, 1 parameningeal) were treated and followed for a median period of 9.0 years (range 0.5 – 18.5 years). Pre–treatment ophthalmic co–morbidities were pain (4), dystopia or proptosis (15), ophthalmoplegia (10), eyelid swelling (13), and vision loss worse than 20/200 (3). Only one patient received chemotherapy and wide excision of an eyebrow lesion without radiation, and had no other ophthalmic complications. Twenty patients were treated with both chemotherapy and radiation (total dose 35.0 – 59.4 Gy) for their orbital or sinus tumors. In this group, the following ophthalmic complications were observed in the follow–up period: corneal dryness (16), conjunctival injection (8), cataract (9), orbito–facial bony hypoplasia (7), opportunistic infections (5), enophthalmos from orbital fat atrophy (4), persistent eyelid erythema or cellulitis (4), trichiasis (3), central corneal opacity (4), band keratopathy (2), phthisis bulbi (2), permanent blindness (4), draining periorbital fistula (3), radiation retinopathy (2), eyelid ptosis (2), and strabismus (1). Additionally, one patient with severe exposure keratopathy required a complete tarsorrhaphy, one developed socket contracture following enucleation and tumor debulking, and two had total orbital exenteration for progressive disease. Conclusions: Over a 32–year period, the combination of chemotherapy and radiation has been the most commonly used treatment modality for primary orbital and/or sinus rhabdomyosarcoma. The most frequently observed treatment–induced ophthalmic complications were corneal dryness, conjunctival injection, and cataract. Fortunately, these could be managed with minimal patient morbidity. Surprisingly, vision–threatening complications were infrequently encountered.

Keywords: orbit • oncology • radiation therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×